Sinotherapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	479.94	511.08	299.41	246.69	314.38	316
Other Revenue	0.54	0.54	0.46	0.87	1.09	3.16
Revenue	480.48	511.62	299.87	247.56	315.47	319.16
Revenue Growth (YoY)	6.98%	70.61%	21.13%	-21.53%	-1.16%	129.84%
Cost of Revenue	265.47	246.11	133.5	68.44	70.44	61.41
Gross Profit	215	265.51	166.37	179.12	245.03	257.75
Selling, General & Admin	57.27	55.25	43.93	43.9	45.71	56.75
Research & Development	71.34	84.92	74.01	76.02	103.63	75.8
Other Operating Expenses	0.91	2.19	3.03	-0.63	0.77	2.02
Operating Expenses	128.24	146.02	122.07	120.91	149.94	135.08
Operating Income	86.76	119.48	44.3	58.21	95.1	122.66
Interest Expense	-0	-0	-0.04	-0.21	-0.23	-
Interest & Investment Income	18.74	16.38	17.45	25.02	5.66	26.16
Currency Exchange Gain (Loss)	2.07	2.07	1.26	5.52	-4	-12.08
Other Non Operating Income (Expenses)	-1.93	-0.07	-0.06	-0.05	0.43	-0.59
EBT Excluding Unusual Items	105.64	137.86	62.91	88.48	96.95	136.15
Gain (Loss) on Sale of Investments	-	-	-	-	0.46	-
Gain (Loss) on Sale of Assets	-0.62	-0.59	-0.11	0.12	-0.02	0.04
Asset Writedown	-1.91	-0.92	-1.62	-0.85	-0.1	-0.09
Other Unusual Items	6.33	5.74	4.8	9.73	51.72	6.22
Pretax Income	109.44	142.08	65.99	97.48	149.01	142.32
Income Tax Expense	10.85	14.38	4.92	4.54	14.1	19.02
Net Income	98.59	127.7	61.07	92.93	134.92	123.3
Net Income to Common	98.59	127.7	61.07	92.93	134.92	123.3
Net Income Growth	-10.02%	109.09%	-34.28%	-31.12%	9.42%	2558.14%
Shares Outstanding (Basic)	465	456	470	422	409	408
Shares Outstanding (Diluted)	465	456	470	422	409	408
Shares Change (YoY)	-0.93%	-2.92%	11.22%	3.32%	0.21%	-
EPS (Basic)	0.21	0.28	0.13	0.22	0.33	0.30
EPS (Diluted)	0.21	0.28	0.13	0.22	0.33	0.30
EPS Growth	-9.17%	115.39%	-40.91%	-33.33%	10.00%	2900.00%
Free Cash Flow	34.18	35.3	-26	-103.15	129.77	171.7
Free Cash Flow Per Share	0.07	0.08	-0.06	-0.24	0.32	0.42
Dividend Per Share	0.062	0.062	0.041	0.062	-	-
Dividend Growth	-6.06%	51.22%	-33.87%	-	-	-
Gross Margin	44.75%	51.90%	55.48%	72.35%	77.67%	80.76%
Operating Margin	18.06%	23.35%	14.77%	23.51%	30.14%	38.43%
Profit Margin	20.52%	24.96%	20.37%	37.54%	42.77%	38.63%
Free Cash Flow Margin	7.11%	6.90%	-8.67%	-41.67%	41.13%	53.80%
EBITDA	101.48	137.79	67.38	83.75	121.21	135.27
EBITDA Margin	21.12%	26.93%	22.47%	33.83%	38.42%	42.38%
D&A For EBITDA	14.72	18.3	23.08	25.55	26.12	12.61
EBIT	86.76	119.48	44.3	58.21	95.1	122.66
EBIT Margin	18.06%	23.35%	14.77%	23.51%	30.14%	38.43%
Effective Tax Rate	9.92%	10.12%	7.45%	4.66%	9.46%	13.36%
Revenue as Reported	480.48	511.62	299.87	247.56	315.47	319.16
Advertising Expenses	-	0.77	0.42	0.69	-	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.